bioRxiv Science⌕ Search

Biology subjects

Olivero, A.

Publications and source records attributed to Olivero, A..

2 recordsLinked to original sources

Fluorescence imaging-induced phospholipid oxidation drives membrane phase separation by shifting miscibility boundaries

Fluorescence microscopy is a widely used tool for visualizing membrane organization in model and cellular systems; however, photoexcitation during imaging can generate reactive oxygen species, thereby altering membrane structure. Here, we show that fluorescence imaging actively drives membrane phase separation through photo-induced phospholipid oxidation. Using giant unilamellar vesicles, we observed that illumination of initially homogeneous membranes triggers the emergence of coexisting liquid-ordered and liquid-disordered domains. Chemical analysis by thin layer chromatography and mass spectrometry revealed the formation of a complex mixture of oxidized lipid species following excitation, characterized by stepwise oxygen additions to unsaturated phospholipids and multiple degradation products. These modifications increase lipid polarity and disrupt acyl chain packing, reducing favorable interactions with saturated phospholipids. As a result, membranes near the miscibility boundary become prone to demixing upon illumination, indicating that photo-induced lipid oxidation effectively shifts the miscibility boundary. Consistent with this model, light-induced phase separation is highly sensitive to membrane composition, with maximal effects observed near the liquid-liquid miscibility boundary. Electroformation substrate further modulated this effect, suggesting that pre-existing oxidative conditions sensitize membranes to subsequent photo-induced changes. Together, these findings demonstrate that excitation light can introduce artifacts in membrane phase behaviour. More broadly, subtle chemical modifications of phospholipids can shift membrane miscibility and reorganize membrane structure.

biochemistry↗

RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy

PIK3CA is one of the most frequently mutated oncogenes; the p110 protein it encodes plays a central role in tumor cell proliferation and survival. Small molecule inhibitors targeting the PI3K p110 catalytic subunit have entered clinical trials, with early-phase GDC-0077 (Inavolisib) studies showing anti-tumor activity and a manageable safety profile in patients with PIK3CA-mutant, hormone receptor-positive breast cancer as a single agent or in combination therapy. Despite this, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression, resulting in enhanced apoptosis and greater efficacy. This unique mechanism against mutant p110 reveals a new strategy for creating inhibitors that specifically target mutant tumors with selective degradation of the mutant oncoprotein and also provide a strong rationale for pursuing PI3K degraders in patients with HER2-positive breast cancer.

cancer biology↗